Human serum versus human serum albumin supplementation in human islet pretransplantation culture: in vitro and in vivo assessment by Nacher, Montserrat et al.
343
Cell Transplantation, Vol. 25, pp. 343–352, 2016 0963-6897/16 $90.00 + .00
Printed in the USA. All rights reserved. DOI: http://dx.doi.org/10.3727/096368915X688119
Copyright Ó 2016 Cognizant, LLC. E-ISSN 1555-3892
 www.cognizantcommunication.com
Received June 11, 2014; final acceptance April 29, 2015. Online prepub date: May 7, 2015.
Address correspondence to Eduard Montanya, Department of Clinical Sciences, Campus de Bellvitge, University of Barcelona, 08907 L’Hospitalet de 
Llobregat, Barcelona, Spain. Tel: +34-93-4037265; Fax: +34-93-2607561; E-mail: montanya@ub.edu
Human Serum Versus Human Serum Albumin Supplementation in Human 
Islet Pretransplantation Culture: In Vitro and In Vivo Assessment
Montserrat Nacher,*† Elisabet Estil·les,*† Ainhoa Garcia,†‡ Belen Nadal,†‡¶ Mar Pairó,*† 
Cristofer Garcia,* Lluís Secanella,* Anna Novials,†‡§ and Eduard Montanya*†¶
*Hospital Universitari Bellvitge-IDIBELLL, Hospitalet de Llobregat, Barcelona, Spain
†CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) Barcelona, Spain
‡Diabetes and Obesity Laboratory, Institut d’Investigacions Biomèdiques  
August Pi I Sunyer (IDIBAPS), Barcelona, Spain
§Hospital Clínic, Barcelona, Spain
¶University of Barcelona, Barcelona, Spain
There is conflicting evidence favoring both the use of human serum (HS) and of human serum albumin (HSA) 
in human islet culture. We evaluated the effects of HS versus HSA supplementation on 1) in vitro b-cell viabil-
ity and function and 2) in vivo islet graft revascularization, islet viability, b-cell death, and metabolic outcome 
after transplantation. Islets isolated from 14 cadaveric organ donors were cultured for 3 days in CMRL 1066 
medium supplemented with HS or HSA. After 3 days in culture, b-cell apoptosis was lower in HS group 
(1.41 ± 0.27 vs. 2.38 ± 0.39%, p = 0.029), and the recovery of islets was 77 ± 11% and 54 ± 1% in HS- and HSA-
cultured groups, respectively. Glucose-stimulated insulin secretion (GSIS) was higher in HS group (29.4, range 
10.4–99.9, vs. 22.3, range 8.7–70.6, p = 0.031). In vivo viability and revascularization was determined in HS- 
and HSA-cultured islets transplanted into the anterior chamber of the eye of Balb/c mice (n = 14), and b-cell 
apoptosis in paraffin-embedded mouse eyes. Islet viability and b-cell apoptosis were similar in both groups. 
Revascularization was observed in one graft (HS group) on day 10 after transplantation. Islet function was 
determined in streptozotocin (STZ)-diabetic nude mice (n = 33) transplanted with 2,000 IEQs cultured with 
HS or HSA that showed similar blood glucose levels and percentage of normoglycemic animals over time. In 
conclusion, human islets cultured in medium supplemented with HS showed higher survival in vitro, as well as 
islet viability and function. The higher in vitro survival increased the number of islets available for transplan-
tation. However, the beneficial effect on viability and function did not translate into an improved metabolic 
evolution when a similar number of HSA- and HS-cultured islets was transplanted.
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INTRODUCTION
Clinical islet transplantation has improved substan-
tially, and a majority of patients achieve stable and near 
normal glycemic control in the absence of severe hypo-
glycemic events with improved quality of life and benefi-
cial effects on chronic complications (36). Nevertheless, 
the function of transplanted islets declines progressively, 
and after several years most patients show a relapse of 
hyperglycemia. Several factors may contribute to the 
progressive loss of graft function, such as chronic rejec-
tion, recurrence of the autoimmune process, and b-cell 
toxicity of immuno suppressive treatment (27). The long-
term outcome of islet transplantation is also determined 
by the amount and quality of the initially transplanted 
tissue (44). A critical number of islets is required to 
attain glycemic control (39), but also to maintain it in 
the long term as shown in animal models (9,45) and in 
clinical human islet transplantation (26,44). Despite the 
improvement in islet isolation procedure, the current 
yield of a single islet isolation is usually insufficient to 
achieve normoglycemia after transplantation to diabetic 
patients. The isolation process results in substantial islet 
injury and death (8), and an additional islet loss takes 
place in the short-term 2- to 3-day culture usually per-
formed before islet transplantation (13,31). This pre-
transplantation culture offers several advantages, among 
them the planning of the transplantation procedure with 
patient pretreatment, the assessment of islet quality, and 
islet shipping to a transplant center, and it has become 
a standard procedure in clinical islet transplantation. 
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However, it has been generally associated with a decline 
in islet viability, islet mass (20,25,42), and b-cell func-
tion (34,41), even though improved viability and func-
tion has also been reported (22).
The addition of bovine serum to the culture media is 
a well-established procedure in rodent islet cultured to 
improve islet viability and function. Serum contains albu-
min, growth factors, extracellular matrix components, and 
it has an inhibitory action on endogenous (38) and exog-
enous enzymes (4). However, xenogeneic bovine serum 
cannot be added to culture media when human islets are to 
be used for clinical transplantation, and the culture media 
is then usually supplemented with human serum albumin 
(HSA) (19,21). It has been hypothesized that supplemen-
tation with human serum (HS) may offer some advantages 
over HSA, and some studies have reported increased islet 
viability, insulin content, and insulin secretion with HS 
(2,16,17,24,41). Nevertheless, other groups have found a 
negative effect of bovine serum (7) and HS (29) supple-
mentation on human islets and better results with serum-
free medium (46). Thus, there is no clear consensus on 
the potential advantages of HS over HSA for human islet 
culture. Moreover, there is very limited information on 
the impact of pretransplantation culture with HS or HSA 
on the outcome of islets if they are subsequently trans-
planted (3), since the vast majority of studies have been 
performed in vitro at the end of the culture period. The 
aim of our study was to determine whether supplementa-
tion of culture medium with HS could increase the viabil-
ity and function of human islets and improve the outcome 
of islet transplantation.
MATERIALS AND METHODS
Human Islet Isolation and Culture Conditions
Pancreatic islets were isolated from 14 adult cadaveric 
organ donors (mean age 57.3 ± 14.6 years, seven females 
and seven males) by collagenase digestion (Collagenase 
NB1 Premium Grade with Neutral Protease NB; Serva 
Electrophoresis GmbH, Heidelberg, Germany) using the 
Ricordi method (37) with some modifications (17). The 
islets were purified on a refrigerated COBE 2991 cell pro-
cessor (COBE BCT, Lakewood, CO, USA) with a continu-
ous density gradient. Islet yield was quantified by dithizone 
staining (Sigma-Aldrich, St. Louis, MO, USA) in duplicate 
using a standard islet diameter of 150 mm as one islet equiva-
lent (IEQ). Immediately after purification, islets were seeded 
in 25-cm2 culture flasks (Sarstedt AG & Co, Nümbrecht, 
Germany) and cultured free floating in Connaught Medical 
Research Laboratories 1066 (CMRL1066) medium (5.6 mM 
glucose) (Mediatech Inc., Corning Cellgro, Manassas, VA, 
USA) supplemented with 2 mM l-Glutamine (Life Tech-
nologies, Grand Island, NY, USA), 10 mM HEPES (Bio-
logical Industries, Kibbutz BeitHaemek, Israel), 40 mg/ml 
gentamycin (Laboratorios Normon, Madrid, Spain), 0.25 mg/
ml amphotericin B (Fungizone; Life Technolo gies), 20 mg/ 
ml ciprofloxacin (Fresenius-Kabi, Barcelona, Spain), 10 
mM nicotinamide (Sigma-Aldrich), and with 0.5% HSA 
(Grifols, Barcelona, Spain) (HSA group) or with 10% ABO-
compatible HS (Blood and Tissue Bank, BST, Barcelona, 
Spain) (HS group) at 37°C and 5% CO2 in a humidified 
incubator for 3–4 days. Culture media was changed every 
2 days.
Study Design
HS- and HSA-cultured islets were compared 1) in vitro 
after 1 and 3 days in culture to determine islet viability 
and b-cell apoptosis and function; 2) after transplantation 
into the anterior chamber of the eye of Balb/c mice to 
determine islet cell viability and graft revascularization 
in vivo, as well as b-cell apoptosis; 3) after transplanta-
tion under kidney capsule of immunodeficient nude mice 
treated with streptozotocin (STZ) (Sigma-Aldrich) to 
induce diabetes, to determine islet function in vivo. The 
experiments were approved by the local Ethics Committee 
and the Animal Ethics Committee.
In Vitro Studies in Cultured Islets
Islet Cell Viability and b-Cell Apoptosis. Islets were 
cultured in groups of 2,800 IEQs in 25-cm2 nontreated 
flasks. After 1 and 3 days in culture, islet cell viability was 
determined by acridine orange/propidium iodide (AO/
PI) staining (Sigma-Aldrich) (5). A 50-islet aliquot was 
transferred in phosphate-buffered saline (PBS) (Biological 
Industries) to a 10 × 35-mm Petri dish (Greiner Bio-One, 
Frickenhausen, Germany). Acridine orange and propidium 
iodide stock solutions were added at a final concentration 
of 0.67 mM and 75 mM, respectively. Acridine-positive 
cells (green) were identified as viable cells and propidium 
iodide-positive cells (red) as dead cells. Islet cell viability 
was expressed as percentage of viable cells versus the total 
(viable and nonviable) islet cells.
b-Cell apoptosis was determined in islets cultured for 
3 days. Islets were fixed overnight in 4% paraformaldehyde 
(Merck KGaA, Darmstadt, Germany) at 4°C, embedded in 
paraffin, and then sectioned and stained for immunofluo-
rescence. Sections were double stained for apoptotic nuclei 
with the terminal deoxynucleotidyl transferase biotin-dUTP 
nick-end labeling (TUNEL) technique (In Situ Cell Death 
Detection Kit, ApopTag; Millipore, Temecula, CA, USA), 
and for insulin with a rabbit polyclonal anti-insulin antibody 
(Santa Cruz Biotechnology Inc., Dallas, TX, USA) (final 
dilution 1:100). For insulin labeling, the secondary antibody 
was a donkey anti-rabbit IgG conjugated with Alexa Fluor 
555 (Life Technologies) (final dilution 1:400). Nuclei were 
stained with 300 nM DAPI (Life Technologies).
b-Cells and TUNEL-positive b-cells were counted 
using a Leica DM4000B microscope connected to a digital 
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camera (Leica DFC 310FX) (Wetzlar, Germany) with 
a color monitor. b-Cell apoptosis was expressed as per-
centage of TUNEL-positive b-cells. A minimum of 1,200 
cells per sample were counted; the sections were sys-
tematically sampled, and when needed, a second section 
was included.
Glucose-Stimulated Insulin Secretion (GSIS). After 1 
and 3 days in culture, the islets were washed with Krebs–
Ringer bicarbonate buffer (NaCl, NaHCO3, CaCl2, 2H2O 
from Sigma-Aldrich and KCl, MgCl2 from Merck KGaA) 
supplemented with HEPES (Sigma-Aldrich) (KRBH) 
and with 2.8 mM glucose (Sigma-Aldrich). Then trip-
licate groups of 10 islets were incubated in borosili-
cate vials containing 1 ml KRBH with 2.8 mM glucose 
(Sigma-Aldrich) for 1 h in a shaking water bath at 37°C 
(stabilization period). The medium was gently removed 
and replaced by 1 ml KRBH containing 2.8 mM glucose, 
and the islets were incubated again for 1 h (basal secre-
tion). The medium was collected and replaced by KRBH 
20 mM glucose, and islets were incubated for an additional 
hour (stimulated secretion). The medium was collected 
and stored at −80°C until insulin quantification by ELISA 
(Mercodia, AB, Uppsala, Sweden).
Insulin and DNA Content. After the GSIS assay, islets 
were washed with phosphate-buffered saline (PBS) (PAA 
Laboratories GmbH, Pasching, Austria) and sonicated in 
1 ml bidistilled water. For insulin content, an aliquot of 
the homogenate was extracted with acid-ethanol solu-
tion and stored at −80°C until insulin quantification by 
ELISA. The remaining homogenate was stored at −80°C, 
and DNA content was measured in 0.1 ml of homogenate 
with a fluorimetric assay using 0.1 mg/ml Hoechst 33258 
(Sigma-Aldrich) (excitation wave length 356 nm and 
emission wave length 448 nm) on a fluorescence spectro-
photometer (F-2000; Hitachi Ltd, Tokyo, Japan).
Islet Transplantation Into the Anterior 
Chamber of the Eye
Islets were transplanted into the anterior chamber of 
the eye to determine the effect of islet culture with HS 
or HSA on islet cell death and on graft revascularization. 
Human islets from three different isolations, cultured for 
4 days with HSA or HS as described above, were labeled 
with a nontoxic fluorescent cell tracer (Vybrant CFDA 
SE; Molecular Probes, Life Technologies) (10 mM) for 15 
min, incubated overnight at 37°C/CO2 5% in a humidified 
incubator, and transplanted into the anterior chamber of the 
eye of normoglycemic Balb/c mice (Harlan Laboratories, 
Horst, The Netherlands) weighing approximately 20 g 
(male, age range 7–13 weeks old) (n = 13). For trans-
plantation, groups of 150–200 islets were collected into 
a polyethylene tube (Smiths Medical International, Kent, 
UK) that was connected to a Hamilton syringe and were 
carefully injected into the anterior chamber of the eye of 
anesthetized animals through a corneal incision previously 
performed with a 27 gauge needle (BD, Madrid, Spain) 
(40). The anterior chamber of the eye had been considered 
an immunoprivileged site (40), and immunosuppressant 
was not administered to transplant recipients.
Graft Revascularization and Islet Cell Death. Ten to 
14 days after transplantation, rhodamine B isothiocyanate-
dextran (Sigma-Aldrich) (2 mg), propidium iodide (Life 
Technologies) (50 mg), and Hoescht (Life Technologies) 
(250 mg) were injected intravenously in each mouse for 
in vivo assessment of transplanted islet vascularization 
and b-cell death quantification. Simultaneous two-photon 
LSM (TPLSM) (Leica Microsystems, Wetzlar, Germany) 
was used to capture optical sections at different depths 
in transplanted islets. To determine vascularization, the 
presence of functional blood vessels, labeled with rho-
damine B isothiocyanate-dextran (red), was identified in 
Vybrant-labeled islets (green), and the number of trans-
planted islets with functional vessels was assessed. Islet 
cell death was determined by counting the nuclei labeled 
with propidium iodide, and results were expressed as 
number of dead cells per square mm of islet graft area. 
Mice were subsequently sacrificed, and the eyes harbor-
ing the transplanted islets were harvested, fixed over-
night in 4% paraformaldehyde at 4°C, and processed for 
paraffin embedding. Eye sections were double stained 
for apoptotic nuclei with the TUNEL technique (In Situ 
Cell Death Detection Kit, ApopTag), and for insulin as 
described above. Total b-cells and TUNEL-positive 
b-cells were counted using a Leica DM4000B micro-
scope connected to a digital camera (Leica DFC 310FX) 
with a color monitor. b-Cell apoptosis was expressed as 
percentage of TUNEL positive b-cells.
Islet Transplantation Into Nude Mice
Human islets were transplanted under the kidney cap-
sule of nude mice to investigate the effect of pretrans-
plantation islet culture with HS or HSA on the metabolic 
outcome of the graft. Islets isolated from four different 
donors were cultured in parallel for 3–4 days with HS 
(n = 17) or with HSA (n = 16) in nonadherent platelet cul-
ture bags (Fenwal Europe SPRL, Mont Saint Guibert, 
Belgium). After 3–4 days in culture, 2,000 IEQs were 
counted and transplanted under the kidney capsule of 
athymic nude-Foxn1nu mice (male, age range 7–23 weeks 
old) (Harlan Laboratories, Horst, The Netherlands) housed 
under specific pathogen-free conditions. To determine the 
potential impact of culture conditions (HSA vs. HS) on the 
endocrine and nonendocrine cell populations, a sample of 
cultured cells was collected as for transplantation at the 
end of the culture period (n = 4 in each group), and it was 
pelleted by centrifugation, fixed in 4% paraformaldehyde 
(Merck KGaA), and processed for paraffin embedding. 
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Sections of the pelleted cell preparations were stained with 
antibodies for insulin (Santa Cruz Biotechnology, Inc.), a 
cocktail for glucagon (Cell Signaling Technology, Inc., 
Leiden, The Netherlands), somatostatin (Dako, Glostrup, 
Denmark), and pancreatic-polypeptide (PP) (Chemicon, 
Merck Millipore, Darmstadt, Germany), and for amylase 
(Sigma-Aldrich) and cytokeratin 19 (Dako). Stained cells 
were counted under the microscope, and the results were 
expressed as percent number of each cell type over total 
cell number.
Ten to 14 days after transplantation, mice were intra-
peritoneally injected with five consecutive daily doses of 
STZ (Sigma-Aldrich), 70 mg/kg body weight (total dose 
of 350 mg/kg), freshly dissolved in citrate buffer (Sigma-
Aldrich) (pH = 4.5), as previously reported (28). A control 
group of nontransplanted mice was also injected with STZ. 
Human islets are known to be exceedingly resistant to STZ 
(48), and in preliminary experiments we confirmed that 
this dose of STZ did not induce b-cell damage (data not 
shown). Thus, after STZ injection that selectively depleted 
the rodent pancreas from b-cells but preserved the STZ-
resistant human b-cells of transplanted islets (48), glucose 
control was dependent on the function of transplanted 
human islets. Blood glucose was determined between 
9:00 and 11:00 A.M. in nonfasting conditions. Blood was 
obtained from the snipped tail, and glucose was measured 
with a portable meter (Glucocard Memory; A. Menarini 
Diagnostics, Barcelona, Spain). Ani mals were considered 
hyperglycemic when blood glucose values were >11.1 mM 
on two consecutive measurements. Grafts were harvested 
60 days after STZ injection. After graft harvesting, blood 
glucose was determined to assess the appearance or wors-
ening of hyperglycemia.
Statistical Analysis
Statistical analysis was performed using Prism 5.0 
(GraphPad, La Jolla, CA, USA). Results are expressed as 
mean ± SEM (islet cell viability and b-cell apoptosis) and 
as medians with range (glucose-stimulated insulin secre-
tion results and cell death in islet grafts after transplan-
tation into the anterior chamber of the eye). In figures, 
mean ± SEM is given to describe the data as it is a bet-
ter known and more widely used descriptor. Differences 
between groups were analyzed using the Student’s t-test, 
the Wilcoxon test for paired samples, the Mann–Whitney 
test for nonpaired samples, and the chi-square test, as 
appropriate. For multiple comparisons, de Kruskal–Wallis 
one-way analysis of variance was used, and if statistically 
significant the post hoc Dunn’s test for multiple compari-
son was subsequently used to adjust for multiple testing. 
The Kaplan–Meier method was used to analyze the meta-
bolic evolution after transplantation, and the differences 
among the survival curves were compared by the log-rank 
test. A value of p < 0.05 was determined as significant.
RESULTS
Islet Cell Viability and b-Cell Apoptosis in 
Cultured Islets
Islet cell viability was similar after 1 day in culture 
with media supplemented with HS (80.8 ± 4.4%) or with 
HSA (75.2 ± 4.5%) (Fig. 1A). In contrast, after 3 days in 
culture, viability was higher in islets cultured with HS 
than with HSA (91.7 ± 1.9% vs. 75.3 ± 5.6% p = 0.049), 
and b-cell apoptosis was lower (1.41 ± 0.27% vs. 2.38 ± 
0.39%, p = 0.029) (Fig. 1B).
Glucose-Stimulated Insulin Secretion
Glucose stimulated insulin secretion and stimulation 
index (ratio of insulin secretion at 20 mM vs. 2.8 mM glu-
cose) was similar in islets cultured with HS and with HSA 
Figure 1. Islet cell viability and apoptosis. Islet cell viability (A) 
and b-cell apoptosis at day 3 (B) in human islets cultured with 
CMRL media supplemented with human serum albumin (HSA, 
open columns) or with human serum (HS, black columns). Islet 
cell viability is expressed as percentage of viable cells (acridine 
orange-positive/propidium iodide-negative cells) over total cells 
within each islet. Values are mean ± SEM of six different islet iso-
lations with islets from each donor cultured in parallel in both con-
ditions. Paired Student t-test, *p = 0.049 (A) and *p = 0.029 (B).
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after 1 day in culture. In contrast, GSIS was higher in islets 
incubated with HS after 3 days in culture: 29.4 (range: 
10.4–99.9) versus 22.3 (range: 8.7–70.6) ng of insulin/
μg of DNA, p = 0.031 (Fig. 2A). Stimulation index was 
reduced in HSA-cultured islets on day 3 compared to both 
day 1 HSA- and day 1 HS-cultured islets (Kruskal–Wallis, 
p = 0.0063, post hoc Dunn’s test for multiple comparison: 
*p < 0.05) (Fig. 2B). Insulin and DNA content was simi-
lar in HS- and HSA-cultured islets on days 1 and 3 (Fig. 
2C, D).
Islet Vascularization and Cell Death After 
Transplantation Into the Anterior Chamber of the Eye
Functional new vessels were identified in one of four 
grafts of HS-cultured islets and in none of the seven HSA-
cultured islet grafts. In the vascularized graft, functional 
vessels were observed in six out of eight evaluated islets 
(Fig. 3A–C).
Cell death was similar in HS- and HSA-cultured islet 
grafts: 43.4 (range: 0–277.3) versus 0 (range: 0–113.8) 
dead cells/mm2 (Fig. 3D). b-Cell apoptosis was also 
similar in HS-cultured (15 out of 2,017 b-cells) and 
HSA-cultured transplanted islets (6 out of 1,087 b-cells) 
(p = 0.76).
Islet Transplantation Into Nude Mice
The recovery of islets after 1 day in culture was 
91 ± 9% and 86 ± 11%, and on day 3 it was 77 ± 11% and 
54 ± 1% in HS- and HSA-cultured groups, respectively. 
Thus, the initial number of islets required to collect 2,000 
IEQs after 3 days in culture was 2,597 and 3,704 IEQs 
for HS- and HSA-cultured islets, respectively. Pellets of 
cells collected for transplantation at the end of the cul-
ture period with HS and HSA showed similar endocrine 
and nonendocrine cellular composition. The cell compo-
sition in HS and HSA groups was b-cells 42.4 ± 3.81% 
Figure 2. Islet function in culture. Islet function in human islets cultured with CMRL media supplemented with human serum albumin 
(HSA, open columns) or with human serum (HS, black columns). (A) Glucose stimulated insulin secretion. *p = 0.031 (Wilcoxon test). 
(B) Stimulation index (ratio between insulin secretion at 20 mM and at 2.8 mM glucose). Kruskal–Wallis one-way analysis of variance 
p = 0.0063, with post hoc Dunn’s test for multiple comparison: *p < 0.05 between HSA day 1 and day 3 groups, and between HS day 1 and 
HSA day 3 groups. (C) Islet insulin content. (D) Islet DNA content. Values are mean ± SEM of four to six different islet isolations, with 
islets from each donor cultured in parallel in both conditions. Insulin secretion experiments were performed in triplicate.
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versus 39.3 ± 3.00%, endocrine non-b-cells 25.3 ± 4.44% 
versus 20.4 ± 4.57%, ductal cells 11.5 ± 1.70% ver-
sus 15.8 ± 2.37%, and acinar cells 14.8 ± 3.48% versus 
14.0 ± 2.79%, respectively. Blood glucose was signifi-
cantly lower after human islet transplantation (log-rank 
test, p < 0.05), a reduction that is in agreement with previ-
ous indications that human islets transplanted to rodents 
regulate the recipient glycemia at the human set point. 
These lower glycemic levels were maintained after STZ 
injection. In contrast, STZ injection resulted in the rapid 
development of severe hyperglycemia and weight loss in 
the control nontransplanted group, and mice were sac-
rificed for ethical reasons 2 weeks after STZ injection. 
Mice transplanted with human islets remained normogly-
cemic in the initial days after transplantation, and none of 
them died during the 60-day follow-up after STZ injection 
(Fig. 4A). Throughout the study, mean blood glucose was 
similar in mice transplanted with HS- or HSA-cultured 
islets. Mild to moderate nonfasting hyperglycemia devel-
oped progressively in mice transplanted with HS- and 
with HSA-cultured islets. Hyperglycemia was detected 
at days 14 (range: 0–53) and 11 (range: 7–48) after STZ 
injection in HS- and in HSA-cultured groups, respec-
tively, and when grafts were harvested 60 days after STZ 
injection, 88% and 69% of transplanted mice showed 
nonfasting hyperglycemia, respectively (Fig. 4B). After 
Figure 3. Vascularization, viability, and apoptosis of human islets transplanted into the anterior chamber of the eye. In vivo imag-
ing of graft vascularization, islet viability, and b-cell apoptosis in pancreatic islets transplanted into the anterior chamber of the eye. 
(A–C) Noninvasive in vivo imaging of islet vascularization. (A) Vybrant-labeled islets are shown in green. (B) Blood vessels labeled 
with rhodamine B isothiocyanate-dextran in red. (C) Merged image with Hoescht-labeled nuclei in blue (25×). Simultaneous two-
photon LSM (TPLSM) was used to capture optical sections at different depths in the engrafted islets. (D) In vivo islet cell viability. 
Results are expressed as number of dead cells per islet area (mm2). Values are mean ± SEM of human serum albumin (HSA)-cultured 
islets grafts (n = 7) and human serum (HS)-cultured islet grafts (n = 4), (Mann–Whitney test). (E) b-Cell apoptosis in islet grafts. 
Section was double stained for TUNEL (green nuclei) and insulin (red) (magnification 40×).
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graft harvesting, blood glucose increased acutely, indicat-
ing a partial function of the graft, concordant with the 
survival of all transplanted mice and the moderate levels 
of hyperglycemia in both groups.
DISCUSSION
In this study, we have found that supplementation of 
CMRL culture medium with HS resulted in increased 
human islet viability and survival, reduced b-cell apop-
tosis, and higher GSIS compared with HSA supplemen-
tation. The higher in vitro survival of HS-cultured islets 
increased the number of islets available for subsequent 
transplantation. However, the beneficial effect of HS on 
islet viability and function did not lead to an improved 
metabolic evolution when a similar number of HS- and 
HSA-cultured islets was transplanted to immunodeficient 
STZ-diabetic mice, and we did not identify differences in 
grafted b-cell apoptosis or in islet graft vascularization 
after transplantation into the anterior chamber of the eye.
The addition of fetal bovine serum to culture media is 
a standard practice in pancreatic rodent islet culture (2). 
In human islet culture, the use of CMRL media supple-
mented with 10% fetal bovine serum is recommended 
(20). However, since the use of xenogeneic products must 
be avoided in clinical islet transplantation, the common 
practice is to supplement the culture media with 0.5% 
human albumin (14,19,21,33), a concentration similar to 
that of albumin in human serum, or even with 1.5% con-
centration (6,35). More recently, some groups have sug-
gested that human AB serum supplementation could be 
superior to HSA. In these studies, the use of HS resulted 
in improved islet viability, lower apoptosis, increased 
insulin secretion or b-cell mass preservation during the 
pretransplantation culture (3,17,24). Serum has an inhibi-
tory effect on pancreatic enzymes and on exogenous 
enzymes, such as caseinolytic enzymes (38) or collage-
nase, that reduce insulin secretion and activate apoptotic 
pathways in islets (4). Moreover, serum contains several 
growth factors that can activate antiapoptotic and mito-
genic pathways in islets, such as growth hormone (18), 
prolactin (47), IGF-1 (15,30), or IGF-2 (12), providing a 
basis for the superior beneficial effects of serum supple-
mentation. However, other studies have shown a detri-
mental effect of serum in human islet culture. It has been 
reported that serum induces a higher production of NO 
in the culture medium and has a negative impact on islet 
function in long-term culture (7). A lower islet recovery 
and insulin secretion has also been found, and it was sug-
gested that the absence of hormones and growth factors 
in islets cultured with albumin keeps cells less meta-
bolically active and less vulnerable to hypoxia (29). Our 
results, in well-standardized culture conditions and paral-
lel experiments with islets isolated from the same donor 
pancreas, clearly show that the use of HS shows superior 
benefits, compared with HSA supplementation, in terms 
of increased islet viability and survival, reduced b-cell 
apoptosis, and better preservation of b-cell function after 
3 days in culture, a similar time period to the one com-
monly used in clinical human islet transplantation.
The beneficial effects of HS supplementation have 
been essentially shown in vitro, and there is a general 
lack of information on whether they may translate into 
an improved graft outcome when islets are transplanted. 
To address this question, we transplanted the same num-
ber of islets previously cultured with HS or with HSA 
Figure 4. Metabolic evolution after human islet transplanta-
tion to STZ-injected nude mice. Metabolic evolution of STZ-
athymic nude mice transplanted with 2,000 IEQs cultured with 
human serum albumin (HSA, black squares) or with human 
serum (HS, open squares) prior to transplantation, and control 
nonislet transplanted mice (circles). (A) Nonfasting blood glu-
cose. Tx indicates transplantation day, STZ indicates streptozo-
tocin injection, and the arrow indicates the removal of the graft. 
Values are mean glucose value at each time point. *p < 0.05 
among nontransplanted and transplanted animals (Mann–
Whitney U-test). (B) Kaplan–Meier survival curve showing 
differences in percentage of normoglycemic animals (log-rank, 
c
2
 = 41.17, p = 0.0001). There were no differences between 
human serum albumin and human serum groups (log-rank, 
c
2
 = 0.17, p = 0.28), that showed a significantly better evolution 
than nontransplanted mice (HSA group log-rank, c2 = 28.87, 
p = 0.0001; HS group log-rank, c2 = 25.48, p = 0.0001).
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to immunodeficient mice in which diabetes was induced 
with STZ. A critical islet mass of 2,000 IEQs was trans-
planted, sufficient to initially maintain normoglycemia 
in most animals but insufficient to sustain it over time. 
It must be noted that due to the different islet survival in 
culture, the initial number of IEQs required to transplant 
2,000 IEQs was 42.6% higher in the HSA-cultured group 
(2,597 vs. 3,703 IEQs). HS- and HSA-cultured islets 
were able to maintain normoglycemia initially after STZ 
injection, but mild hyperglycemia gradually developed 
in most animals and at a similar time and rate. When 
islet grafts were harvested, 60 days after STZ injection, 
the percentage of hyperglycemic animals and the level 
of hyperglycemia were similar in both groups. After islet 
graft harvesting, severe hyperglycemia and weight loss 
developed in both groups, confirming the partial func-
tion of transplanted grafts, and again, no differences 
were identified between groups. These results indicate 
that the beneficial effects of HS supplementation on islet 
viability and b-cell function that we had identified at the 
end of the culture period did not translate into an identifi-
able metabolic benefit if the same number of islets was 
subsequently transplanted.
Even though the metabolic evolution is the primary 
outcome of interest in islet transplantation, it does not 
provide an indication of the events taking place at the 
graft level. Thus, in order to have a better assessment of 
the potential effects of HS supplementation during the 
pretransplantation culture we determined b-cell viabil-
ity, b-cell apoptosis, and islet revascularization of the 
grafts. Islets were transplanted into the anterior cham-
ber of mouse eye, a transplantation site that allows the 
in vivo assessment of transplanted islet vascularization 
and viability (23,40). Functional revascularization was 
detected in a single graft in islets cultured with HS and in 
none of the HSA-cultured islets. In vivo islet cell viabil-
ity, expressed as number of death cells per graft area was 
similar in both groups. The transplanted islets were then 
harvested and processed for ex vivo specific determina-
tion of b-cell apoptosis in graft sections double stained 
for TUNEL and insulin. In agreement with the in vivo 
data on islet cell viability, b-cell apoptosis was similar 
in islet grafts from HS- and HSA-cultured islets. Thus, 
the transplant experiments did not confirm the superior 
results achieved in vitro when islets were incubated with 
HS.
Strengths of the study include the use of in vitro and 
in vivo models to assess the effect of HSA or HS supple-
mentation. The in vivo experiments included two experi-
mental models, with in vivo and ex vivo evaluation of 
morphological and functional aspects of the graft. Even 
though we did not perform additional measurements in 
islet grafts, such as b-cell replication or islet graft mass, 
it is unlikely that in the absence of differences in cell 
viability, b-cell apoptosis, initial islet revascularization, 
and blood glucose evolution we would have found differ-
ences in these additional parameters. The study has also 
limitations. The 0.5% HSA concentration that we have 
tested is the one commonly used to supplement human 
islet culture before transplantation. However, we cannot 
exclude that a different concentration could yield different 
results (6). In addition, based on initial reports indicating 
that the anterior chamber of the eye was an immunoprivi-
leged site (40), immunosuppression of the recipient was 
not used in these experiments. However, more recent data 
(1) have shown that there is only partial immunoprotec-
tion of the transplanted islets. Thus, partial rejection of 
xenotransplanted human islets may have had a negative 
impact on the survival and vascularization of the graft, 
reducing the possibilities to detect differences between 
groups transplanted with HS- or HSA-cultured islets.
In summary, the supplementation of culture media 
with HS provided superior benefits compared with HSA 
in terms of islet survival, viability, and function. However, 
when a similar number of HSA- or HS-cultured islets 
were transplanted, we were unable to confirm a benefit in 
vivo. We speculate that the in vitro effects of HS on islet 
cell viability and function may not be sufficient by them-
selves to have a significant impact on transplanted islets 
when they face the difficult conditions of islet implanta-
tion and survival after transplantation (27). We and oth-
ers have shown the difficulty of reducing b-cell death in 
the initial days after islet transplantation (10,11,32,43). 
Nevertheless, the positive in vitro results indicate that 
supplementation of culture medium with HS optimizes 
the number of islets available for transplantation, and it 
may be expected that it could have an additional benefi-
cial impact if used in combination with other strategies to 
improve islet transplantation outcome.
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